The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin; [Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP]
Allopurinol affects the expression of PLN mRNA; Allopurinol affects the expression of PLN protein; Allopurinol affects the expression of PLN protein modified form
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein]
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein]
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein]
pyrazolanthrone inhibits the reaction [Sodium Chloride promotes the reaction [SP1 protein binds to JUN protein]]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of SP1 protein]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
[Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Pantoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of IL6 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL6 protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein] ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein
ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein] ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein] ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein
ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein
TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of CASP8 mRNA]; TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of TRADD mRNA] Ofloxacin results in increased expression of TNFRSF1A mRNA; Ofloxacin results in increased expression of TNFRSF1A protein
AGT protein modified form results in increased susceptibility to Serotonin Deferoxamine inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin]; Reactive Oxygen Species inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin]
silodosin binds to and results in decreased activity of ADRA1A protein; silodosin inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein]
browse the term
